When one company acquires another, its ability to monetize its investment initially is dependent on clinical studies started at the acquired company. However over time, the surviving company will have more say in how it gains from its investment, by putting its stamp on new clinical trials and its use of the acquired technologies.

For example, Gilead Sciences Inc. last week released the latest data from its AmBisome program, acquired